Novartis.com | Contact Us | Help | Site Map | Stay Connected | Large Text VersionRegular Text Version

Welcome to Novartis Oncology - The Global Site for Novartis Oncology

 

 

 

Patients & Caregivers

Gastrointestinal Stromal Tumors

Treatment

Download This Article

 

Surgery is the standard treatment for primary resectable GIST. However, surgical resection is seldom curative, and by 5 years after complete removal of their tumor, half of patients having undergone such cancer treatments treated have relapsed.

Imatinib is the first-line treatment in patients with metastatic or unresectable GIST. It has resulted in durable objective response or stable disease in approximately 85% of patients with advanced GIST and is well tolerated.

 previous section | next section ›

 

PRODUCTS

At Novartis Oncology, we strive to provide a broad range of innovative, practical solutions and authoritative resource therapies.

PATIENT STORIES

Patient Stories

"My sister died of breast cancer years ago. I'm a cancer survivor-because the battle is a lot different today."
- Carol Lundin

RESEARCH INNOVATION

Novartis maintains the most promising oncology drug pipeline in the industry to treat and help people around the world.